Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP2013 versus MabThera with CVP followed by maintenance in previously untreated advanced follicular lymphoma
2010-019522-13Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rituximab in follicular lymphoma (FL) (2 arms), sponsored by Hexal AG. Primary endpoint: Overall response rate. Started Aug 2011; status: completed.
02
Drugs
rituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2010-019522-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019522-13.